130 related articles for article (PubMed ID: 7839634)
21. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
Tiseo M; Boni L; Ardizzoni A
J Clin Oncol; 2005 Sep; 23(25):6276-7; author reply 6277-8. PubMed ID: 16135504
[No Abstract] [Full Text] [Related]
22. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
[TBL] [Abstract][Full Text] [Related]
23. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
Cure H; Dauplat J; Cholet P
Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
[TBL] [Abstract][Full Text] [Related]
24. Platinum-based chemotherapy in metastatic breast cancer: current status.
Decatris MP; Sundar S; O'Byrne KJ
Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
26. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Jost LM; Honegger HP; Stahel RA
Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
[TBL] [Abstract][Full Text] [Related]
27. [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Hosomi Y; Shibuya M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1352-6. PubMed ID: 11681241
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
29. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
31. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
33. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
34. [A meta-analysis of the curative effects of carboplatin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer].
Jiang JW; Liang XH; Zhou XL; Huang RF
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2615-20. PubMed ID: 17198587
[TBL] [Abstract][Full Text] [Related]
35. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Imataki O; Aoyama T; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
[TBL] [Abstract][Full Text] [Related]
37. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
38. Clinical trials of myeloma treatment: a review.
Osby E; Reizenstein P
Drugs Exp Clin Res; 1986; 12(1-3):113-8. PubMed ID: 3525066
[TBL] [Abstract][Full Text] [Related]
39. [Interferon (IFN) in multiple myeloma and non-Hodgkin's lymphoma].
Gola A
Acta Haematol Pol; 1994; 25(2 Suppl 1):136-41. PubMed ID: 7520658
[TBL] [Abstract][Full Text] [Related]
40. [Cisplatin for malignant lymphoma--preliminary observation on 43 patients].
Liu HM
Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):286-8. PubMed ID: 3910379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
